PRLD compared with EWTX: revenue, margins and what each company keeps, and the suppliers and customers both name

PRLDPrelude Therapeutics Inc

Mkt capRevenueRevenue

EWTXEdgewise Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

PRLDPrelude Therapeutics Inc

EWTXEdgewise Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

PRLD1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±17.9%▲+10.14%×0.56

EWTX

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±11.6%▼−1.27%×0.11

May 7 '26±8.8%▼−3.81%×0.43

= impliedPRLD realized, solidEWTX realized, hatchedOne scale, both sides: full bar = 27%× = |realized| ÷ impliedSource: market data

Q1 FY26

±13.2%

▼−1.53%

×0.11

Nov 6 '25±27.0%▼−1.61%×0.06

PRLDPrelude Therapeutics Inc

3.89· pre 3.89· delayed

Mkt cap$309.6MRevenue$6MQ2 FY26

EWTXEdgewise Therapeutics, Inc.

38.93· pre 39.06· delayed

Pre-marketOct 30 '26delayed

Mkt cap$4.2BRevenue—

Compare

Pre-marketOct 30 '26delayed

PRLDPrelude Therapeutics Inc

EWTXEdgewise Therapeutics, Inc.

3.89pre 3.89delayed

Price

38.93pre 39.06delayed

$309.6M

Mkt cap

$4.2B

Q2 FY26$6M

Revenue

—

PRLD3.89vsEWTX38.93Pre-marketOct 30 '26delayed